Progyny, Inc.

{
  "main_header": {
    "sid": 1242894,
    "name": "Progyny, Inc.",
    "stock_name": "Progyny, Inc.",
    "full_name": "Progyny, Inc.",
    "name_url": "stocks-analysis/progyny-inc",
    "exchange": 1,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "25.45",
    "chg": 3.48,
    "chgp": "15.84%",
    "dir": 1,
    "prev_price": "21.97",
    "mcapval": "1,964.70",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Miscellaneous",
    "ind_code": 3205,
    "indexname": "S&P 500",
    "isin": "US74340E1038",
    "curr_date": "Jan 21",
    "curr_time": "",
    "bse_nse_vol": "2.36 M",
    "exc_status": "Active",
    "traded_date": "Jan 21, 2026",
    "traded_date_str": "2026 01 21",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/progyny-inc-1242894-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Progyny, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-progyny-inc-overvalued-or-undervalued-3689290",
        "imagepath": "",
        "date": "2025-11-11 11:34:21",
        "description": "As of 7 November 2025, Progyny, Inc. has moved from a fair to an expensive valuation grade. The company appears to be overvalued, with a P/E ratio of 35, a Price to Book Value of 3.98, and an EV to EBITDA ratio of 20.94. In comparison to peers, Progyny's P/E ratio is significantly higher than ADT, Inc. at 10.02 and MAXIMUS, Inc. at 15.70, indicating that it is priced at a premium relative to its industry counterparts.\n\nDespite a strong recent performance, with a 1-year return of 42.20% compared to the S&P 500's 12.65%, the long-term outlook shows a concerning trend, as the stock has underperformed over 3 and 5 years with returns of -37.28% and -18.58%, respectively. This suggests that while the company has had short-term gains, its long-term valuation may not be justified given its current metrics...."
      },
      {
        "title": "Progyny, Inc. Hits Day High with 24.21% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/progyny-inc-hits-day-high-with-2421-surge-in-stock-price-3686569",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ProgynyInc_priceRelatedfactors_3686569.png",
        "date": "2025-11-10 17:53:29",
        "description": "Progyny, Inc. has shown remarkable stock performance, significantly outperforming the S&P 500 over various timeframes. The company reports strong financial fundamentals, including a high Return on Equity and impressive growth rates in net sales and operating profit, alongside a low debt-to-equity ratio and full institutional ownership."
      },
      {
        "title": "Progyny, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/progyny-inc-sees-valuation-grade-shift-from-fair-to-expensive-amid-price-increase-3686319",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ProgynyInc_valuationdot_3686319.png",
        "date": "2025-11-10 16:12:44",
        "description": "Progyny, Inc. has recently adjusted its valuation, with its stock price rising to $22.37. Over the past year, the company has achieved a 35.33% return, outperforming the S&P 500. Key metrics include a P/E ratio of 35 and a return on capital employed of 34.17%, indicating strong financial performance."
      },
      {
        "title": "Is Progyny, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-progyny-inc-overvalued-or-undervalued-3683194",
        "imagepath": "",
        "date": "2025-11-09 11:09:27",
        "description": "As of 7 November 2025, Progyny, Inc. has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its high valuation ratios, including a P/E ratio of 35, a price to book value of 3.98, and an EV to EBITDA of 20.94. In comparison, peers such as ADT, Inc. have a P/E of 10.02 and an EV to EBITDA of 5.12, indicating that Progyny's valuation significantly exceeds that of its more attractively priced competitors.\n\nDespite strong returns in the short term, with a 1-year stock return of 35.33% compared to the S&P 500's 12.65%, the long-term performance shows a concerning trend, as the 3-year and 5-year returns are -44.57% and -17.18%, respectively, against the S&P 500's substantial gains. This suggests that while Progyny may be performing well recently, its overall valuation does not align with its long-term performance, reinforcing the conclusion that it is overval..."
      }
    ],
    "total": 20,
    "sid": "1242894",
    "stock_news_url": "https://www.marketsmojo.com/news/progyny-inc-1242894"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Progyny, Inc. overvalued or undervalued?

2025-11-11 11:34:21

As of 7 November 2025, Progyny, Inc. has moved from a fair to an expensive valuation grade. The company appears to be overvalued, with a P/E ratio of 35, a Price to Book Value of 3.98, and an EV to EBITDA ratio of 20.94. In comparison to peers, Progyny's P/E ratio is significantly higher than ADT, Inc. at 10.02 and MAXIMUS, Inc. at 15.70, indicating that it is priced at a premium relative to its industry counterparts. Despite a strong recent performance, with a 1-year return of 42.20% compared to the S&P 500's 12.65%, the long-term outlook shows a concerning trend, as the stock has underperformed over 3 and 5 years with returns of -37.28% and -18.58%, respectively. This suggests that while the company has had short-term gains, its long-term valuation may not be justified given its current metrics....

Read full news article

Progyny, Inc. Hits Day High with 24.21% Surge in Stock Price

2025-11-10 17:53:29

Progyny, Inc. has shown remarkable stock performance, significantly outperforming the S&P 500 over various timeframes. The company reports strong financial fundamentals, including a high Return on Equity and impressive growth rates in net sales and operating profit, alongside a low debt-to-equity ratio and full institutional ownership.

Read full news article

Progyny, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics

2025-11-10 16:12:44

Progyny, Inc. has recently adjusted its valuation, with its stock price rising to $22.37. Over the past year, the company has achieved a 35.33% return, outperforming the S&P 500. Key metrics include a P/E ratio of 35 and a return on capital employed of 34.17%, indicating strong financial performance.

Read full news article

Is Progyny, Inc. overvalued or undervalued?

2025-11-09 11:09:27

As of 7 November 2025, Progyny, Inc. has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its high valuation ratios, including a P/E ratio of 35, a price to book value of 3.98, and an EV to EBITDA of 20.94. In comparison, peers such as ADT, Inc. have a P/E of 10.02 and an EV to EBITDA of 5.12, indicating that Progyny's valuation significantly exceeds that of its more attractively priced competitors. Despite strong returns in the short term, with a 1-year stock return of 35.33% compared to the S&P 500's 12.65%, the long-term performance shows a concerning trend, as the 3-year and 5-year returns are -44.57% and -17.18%, respectively, against the S&P 500's substantial gains. This suggests that while Progyny may be performing well recently, its overall valuation does not align with its long-term performance, reinforcing the conclusion that it is overval...

Read full news article

View All News